Tolerance induction by acylated peptides: suppression of EAE in the mouse with palmitoylated PLP peptides.
Treatment of SJL mice either before or after challenge with palmitoylated PLP139-151 (PAL139-151) completely suppressed or considerably reduced both acute and relapsing stages of EAE induced with PLP139-151. In the presence of Pertussis toxin, treatment with PAL139-151 was less effective, but treatment with a mixture of PAL139-151 and PAL178-191, the palmitoylated PLP epitope to which T cell recognition spreads, resulted in almost complete protection. Proliferation of lymphocytes from treated mice were sharply reduced, and adoptive transfer of lymph node lymphocytes from treated mice to naive recipients resulted in the reduction of the acute phase of EAE and in delayed relapses following challenge. The results suggest that treatment with PAL139-151 leads to both anergy and the generation of regulatory cells.
Department of Microbiology and Immunology, Health Sciences Centre, and The John P. Robarts Research Institute, University of Western Ontario, N6A 5C1, London, Ont., Canada.
J
J
St  Louis
S
S
Uniyal
L
L
Xu
E
E
Chan
B
B
Singh
B M
BM
Chan
G H
GH
Strejan
D019264:Adoptive Transfer; D000818:Animals; D002455:Cell Division / Q000187:drug effects; D004359:Drug Therapy, Combination; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000139:chemically induced / Q000188:drug therapy* / Q000276:immunology; D018984:Epitopes, T-Lymphocyte / Q000276:immunology; D005260:Female; D005620:Freund's Adjuvant / Q000276:immunology; D007108:Immune Tolerance / Q000187:drug effects* / Q000276:immunology; D007279:Injections, Subcutaneous; D008198:Lymph Nodes / Q000187:drug effects / Q000473:pathology; D008214:Lymphocytes / Q000187:drug effects / Q000276:immunology; D051379:Mice; D008815:Mice, Inbred Strains; D018991:Myelin Proteolipid Protein / Q000008:administration & dosage* / Q000276:immunology / Q000378:metabolism*; D019308:Palmitic Acid / Q000378:metabolism*; D010446:Peptide Fragments / Q000008:administration & dosage* / Q000276:immunology / Q000378:metabolism*; D037342:Pertussis Toxin; D012008:Recurrence; D012720:Severity of Illness Index; D010566:Virulence Factors, Bordetella / Q000008:administration & dosage
D018984:Epitopes, T-Lymphocyte; D018991:Myelin Proteolipid Protein; D010446:Peptide Fragments; D010566:Virulence Factors, Bordetella; C435023:myelin proteolipid protein (139-151); C094242:myelin proteolipid protein (178-191); D019308:Palmitic Acid; D005620:Freund's Adjuvant; D037342:Pertussis Toxin